FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OIVID APP	RUVAL
OMB Number:	3235-0287
Estimated average bu	ırden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

						2. Issuer Name and Ticker or Trading Symbol MEDICINOVA INC [MNOV]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner V Officer (give title Other (specify									
	DICINOVA	, INC.	(Middle)					liest Trans	saction (Mo	onth/I	Day/Year)			X	VP and Head of Japanese Office								
4275 EX	ECUTIVE	SQUARE, SUI	_ 4.	If Ame	endme	ent, Date o	of Original	Filed	(Month/Da	6. Individual or Joint/Group Filing (Check Applicable													
(Street) LA JOLI	MEDICINOVA INC Month/Day/reary Commercial Processing Commercial Proces																						
(City)	(S	State)																					
1. Title of Security (Instr. 3)			Date			Execution Date, if any		, Transa Code (Transaction Code (Instr.		Disposed Of (D) (Instr. 3, 4			Securitie Beneficia Owned F	s Illy ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		Indirect Beneficial Ownership					
								Code	v	Amount	(A) (D)	(A) or (D)		Transacti	ion(s)			(A1541. 4)					
Common	Stock			02/2	28/20	3/2019			М		35,70	00 A	. \$	\$7.34 189		,280		D					
Common	Stock			02/2	28/20	19			M		85,00	00 A	. 4	\$2.54	274	,280		D					
Common	Stock			02/2	28/20	19			M		63,75	50 A	. 4	52.46	338	,030		D					
Common Stock			02/28/2019					M		80,00	00 A	. :	\$4.1	418,030		D							
Common Stock			02/28/2019				M		42,50	00 A	. :	\$4.1	460	,530		D							
Common Stock			02/28/2019				M		105,0	00 A	. \$	\$2.64 5		5,530		D							
Common	Stock			02/2	28/20	19			M		15,00	00 A	. 4	3.24	580	,530		D					
				02/28/2019				M				_		685			D						
				02/2	28/20	19			M		30,00	00 A					_	D					
Common	ommon Stock				28/20	19			M		 	, , , , , , , , , , , , , , , , , , ,		3.91	1		+						
	Table I - N 1. Title of Security (Instr. 3) Common Stock Common Stoc								M		 		_	-	+			D					
Common	C/O MEDICINOVA, INC. 4275 EXECUTIVE SQUARE, SUITE 300 (Street) LA JOLLA CA 9203 (City) (State) (Zip) Table I 1. Title of Security (Instr. 3) Common Stock Comm							<u> </u>											<u> </u>	0,530		D	
			2037 3. Date of Earlest Transaction (Month/Day/Year) 2. Office (give nite below) 2/28/2019 4. If Amendment, Date of Original Filed (Month/Day/Year) 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Repo																				
1. Title of Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative	Date	Execution D	ate,	Transa Code (5. Nu Deriv Instr. Secu Acqu or Di		Derivative Securities Acquired (A) or Disposed of (D) (Instr.		Expiration Date		of Securities Underlying Derivative Sec			Derivative Security	derivative Securities Beneficia Owned Following Reported	e s ally g	Ownership Form: Direct (D) or Indirect	of Indirect Beneficial Ownership (Instr. 4)				
													or				ion(s)						
					Code	v	(A)	(D)				Title											
Employee Stock Option (Right to Buy)	\$7.34	02/28/2019			M			35,700	(1)		01/28/2020		37,	500	\$0	0		D					
Employee Stock Option (Right to Buy)	\$2.54	02/28/2019			M			85,000	(2)		07/12/2021		85,0	000	\$0	0		D					
Employee Stock Option (Right to Buy)	\$2.46	02/28/2019			M			63,750	(3)	(08/02/2021		63,	750	\$0	0		D					
Employee Stock Option (Right to Buy)	\$4.1	02/28/2019			M			80,000	(4)		05/12/2023		80,0	000	\$0	0		D					

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)															
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title an of Securit Underlyin Derivative (Instr. 3 an	ies g : Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Employee Stock Option (Right to Buy)	\$4.1	02/28/2019		M			42,500	(5)	05/12/2023	Common Stock	42,500	\$0	0	D	
Employee Stock Option (Right to Buy)	\$2.64	02/28/2019		М			105,000	(6)	12/11/2023	Common Stock	105,000	\$0	0	D	
Employee Stock Option (Right to Buy)	\$3.24	02/28/2019		М			15,000	(7)	12/03/2024	Common Stock	15,000	\$0	0	D	
Employee Stock Option (Right to Buy)	\$3.09	02/28/2019		М			105,000	(8)	01/06/2025	Common Stock	105,000	\$0	0	D	
Employee Stock Option (Right to Buy)	\$3.91	02/28/2019		М			30,000	(9)	01/06/2026	Common Stock	30,000	\$0	0	D	
Employee Stock Option (Right to Buy)	\$3.91	02/28/2019		М			120,000	(10)	01/06/2026	Common Stock	120,000	\$0	0	D	
Employee Stock Option (Right to Buy)	\$6.1	02/28/2019		М			100,000	(11)	01/17/2027	Common Stock	100,000	\$0	0	D	
Employee Stock Option (Right to Buy)	\$ 7	02/28/2019		М			105,000	(12)	01/05/2028	Common Stock	105,000	\$0	0	D	

Explanation of Responses:

- $1. \ The option vested over a period of 4 years in equal monthly installments from the 1/28/2010 date of grant and is now fully vested.$
- 2. The option vested over a period of 4 years in equal monthly installments from the 7/13/2011 date of grant and is now fully vested.
- $3.\ The\ option\ was\ granted\ on\ 8/3/2011,\ was\ subject\ to\ vesting\ based\ on\ achievement\ of\ performance\ criteria\ and\ vested\ in\ full\ on\ 6/14/2012.$
- $4. \ The option was granted on 5/13/2013, was subject to vesting based on achievement of performance criteria and vested in full on 12/2/2013.$
- 5. The option vested over a period of 4 years in equal monthly installments from the 5/13/2013 date of grant and is now fully vested.
- $6. \ The option was granted on 12/12/2013, was subject to vesting based on achievement of performance criteria and vested in full on 12/4/2014.$
- $7. \ The option vested over a period of 3 years in equal monthly installments from the 12/4/2014 date of grant and is now fully vested.$
- $8. \ The option was granted on 1/7/2015, was subject to vesting based on achievement of performance criteria and vested in full on 1/7/2016.$
- $9. \ The option vested over a period of 3 years in equal monthly installments from the 1/7/2016 date of grant and is now fully vested.$
- 10. The option was granted on 1/7/2016, was subject to vesting based on achievement of performance criteria and vested in full on 1/18/2017. 11. The option was granted on 1/18/2017, was subject to vesting based on achievement of performance criteria and vested in full on 1/6/2018.
- 12. The option was granted on 1/6/2018, was subject to vesting based on achievement of performance criteria and vested in full on 1/15/2019.

/s/ Masatsune Okajima

03/04/2019

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.